Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-10
2008-06-10
Coleman, Brenda L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S278000
Reexamination Certificate
active
07384949
ABSTRACT:
A compound of formula (I), wherein X is S or O; R1is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8, and NR5SO2R8; R2is selected from aryl attached via an unsaturated carbon atom; R3is selected from H, alkyl, hydroxy, alkoxy, halogen, CN and NO2; R4is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO2, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8and NR5SO2R8; R5, R6and R7are independently selected from H, alkyl and aryl or where R6and R7are in an (NR6R7) group, R6and R7may be linked to form a heterocyclic group, or where R5, R6and R7are in a (CONR5NR6R7) group, R5and R6may be linked to form a heterocyclic group; and R8is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, and the use thereof in therapy and in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such a Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or wherein said medicament is for neuroprotection in a subject
REFERENCES:
patent: 6197788 (2001-03-01), Fletcher et al.
patent: 6583156 (2003-06-01), Gillespie et al.
patent: 6608085 (2003-08-01), Gillespie et al.
patent: 6787541 (2004-09-01), Gillespie et al.
patent: 1 221 444 (2002-07-01), None
patent: 1 300 147 (2003-04-01), None
patent: 04-36284 (1992-02-01), None
patent: WO 99/21617 (1999-05-01), None
patent: WO 99/40091 (1999-08-01), None
patent: WO 01/02409 (2001-01-01), None
patent: WO 01/62233 (2001-08-01), None
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Kulisevsky, Jaime; Barbanoj, Manel; Gironell, Alexandre; Antonijoan, Rosa; Casas, Miquel; Pascual-Sedano, Berta, Clinical Neuropharmacology. 25(1):25-31, Jan./Feb. 2002, abstract only.
Morelli, Micaela, Experimental Neurology, 184, 20-23, 2003.
Tuite, Paul et al, Expert. Opin. Investig. Drugs, 12, 1335-1352, 2003.
Bibbiani, F. et al, Experimental Neurology, 184, 285-294, 2003.
Spiros Konitsiotis, Expert. Opin. Investig. Drugs, 14, 377-392 2005.
Anonymous, Drug and Therapeutic Bulletin, 35, pp. 36-40, 1999.
LeWitt, Peter A., Pharmacotherapy, 20, pp. 26S-32S, 2000.
Loscher W.,.Epilepsy Res. Jun. 2002;50(1-2):105-23.
Jennifer L. Hellier, Peter R. Patrylo, Ping Dou, Michelle Nett, Gregory M. Rose, and F. Edward Dudek, J. Neurosci. 1999, 19(22):10053-10064.
Wenning GK, Granata R, Puschban Z, Scherfler C, Poewe W., .J Neural Transm Suppl. 1999;55:103-13, Medline abstract PMID: 10335497.
Rebecca J. Carter et al ,The Journal of Neuroscience, Apr. 15, 1999, 19(8):3248-3257.
Yanamoto H, Nagata I, Niitsu Y, Xue JH, Zhang Z, Kikuchi H., Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique, Exp Neurol. Aug. 2003;182(2):261-74.
Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ ,Melena J., Optic nerve and neuroprotection strategies.Eye. Nov. 2004;18(11):1075-84.
Jenner, Peter, Expert Opin. Investig. Drugs, 14(6), 2005, pp. 729-738.
Bailey et al., “Changes in spinalσ- and κopioid systems in mice deficient in the A2A receptor gene”, Journal of Neuroscience, vol. 22, No. 21, 2002, abstract only.
Bara-Jimenez et al., “Adenosine A2A receptor antagonist treatment of Parkinson's disease”,Neurologyvol. 61, No. 3, 2003, abstract only.
Bastia et al.,Neurosci, vol. 328, No. 3, Lett. 2002 (pp. 241-244).
Behan et al., Br. J. Pharmacology, vol. 135, 2002 (pp. 1435-1442).
Bertorelli et al., “Effects of selective agonists and antagonists for A1 or A2a adenosine receptor on sleep-walking patterns in rats”,Drug Development Research, Wiley-Liss, Inc., Research Articles, vol. 37, 1996 (pp. 65-72).
Chase et al., “Translating A2aantagonist KW6002 from animal models to parkinsonian patients”,Neurology, vol. 61, No. 11, Suppl. 6, abstract only, (2003).
Dall'lgna et al.,Br. J. Pharmacology, vol. 138, 2003 (pp. 1207-1209).
Ei Yacoubi et al.,Br. J. Pharmacology, vol. 134, No. 1, 2001 (pp. 68-77).
Fredholm, B.B. et al., “Actions of caffeine in the brain with special reference to factors that contribute to its widespread use”,Pharmacol. Rev., vol. 51, 1999 (pp. 83-133).
Garfinkel, B.D. et al., “Responses to methylphenidate and varied doses of caffeine in children with attention deficit disorder”,Can. J. Psychiatry, vol. 26, 1981 (pp. 395-401).
Gonzalez-Benitez, European Journal of Pharmacology, vol. 437, Elsevier, 2002 (pp. 105-111).
Hauser et al., “Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD”,Neurology, vol. 61, No. 3, 2003, abstract only.
Hess, “Recent advances in Adenosine Receptor Antagonist Research, Review, Monthly Focus: Central and Peripheral Nervous Systems”,Ashley Publications Ltd., 2001 (pp. 1533-1561).
Ikeda et al., “Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease”,Journal of Neurochemistry, vol. 80, No. 2, 2002 (pp. 262-270).
Kase, “New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia”,Bioscience, Biotechnology, and Biochemistry, vol. 65, No. 7, abstract only, (2001).
Kopf et al., “Adenosine and memory storage: effect of A1 and A2 receptor antagonists”,Psychopharmacology (Berlin), vol. 146, No. 2, 1999 (pp. 214-219).
Ledent et al., “Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor”,Nature, vol. 388, No. 6643, Aug. 14, 1997 (pp. 674-678).
Li et al.,Exp. Eye Res. , vol. 68, Academic Press, 1999 (pp. 9-17).
Mally and Stone,CNS Drugs, vol. 19, No. 5, 1998 (pp. 311-320).
Monopoli et al.,Journal of Pharmacology and Experimental Therapeutics, vol. 255, No., 1, The American Society for Pharmacology and Experimental Therapeutics, 1998 (pp. 9-15).
Monopoli et al.,NeuroReport 9, 1998 (pp. 3955-3959).
Ongini et al., “Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes”,Drug Development Research, vol. 52, No. 1/2, 2001 (pp. 379-386).
Popoli et al., “Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum”,Journal of Neuroscience, vol. 22, No. 5, 2002 (pp. 1967-1975).
Satoh et al., “Involvement of adenosine A2A rreceptor in sleep promotion”,European Journal of Pharmacology, vol. 351, Elsevier, 1998 (pp. 152-162).
Scammel et al., “An adenosine A2a agonist increases sleep and induces fos in ventrolateral preoptic neurons”,Neuroscience, vol. 107 No. 4, Pergamon, 2001 (pp. 653-663).
Schechter, M.D. et al., “Objectively measured hyperactivity—II. Caffeine and amphetamine effects”,J. Clin. Pharmacol., vol. 25, 1985 (pp. 276-280).
Stone et al.,Drug Dev. Res., vol. 52 No. 1/2, 2001 (pp. 323-330).
Svenningsson, P. et al., “Distribution, biochemistry and function of striatal adenosine A2Areceptors”,Prog. Neurobiol., vol. 59, 1999 (pp. 355-3596).
Urade et al., “Sleep regulation in adenosine A2Areceptor-deficient mice”,Neurology, vol. 61, No. 11, Suppl. 6, 2003 (pp. S94-S96).
Varani et al., “Aberrant A2Areceptor function in peripheral blood cells in Huntington's disease”,FASEB Journal, vol. 17, No. 14, 2003 (pp. 2148-2150).
Varani et al.,Collogue Scientifique sur le Café, 2001, 19th(pp. 51-58).
Patent Abstracts of Japan, vol. 016, No. 207
Dawson Claire Elizabeth
Gaur Suneel
Gillespie Roger John
Lerpiniere Joanne
Pratt Robert Mark
Coleman Brenda L.
Foley & Lardner LLP
Moore Susanna
Vernalis Research Limited
LandOfFree
Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2807451